Gene Therapy for Inherited Deafness Shows Sustained Hearing Improvement Over 2.5-Year Follow-Up

In April 2026, an international research team co-led by investigators at Mass General Brigham and the Eye & ENT Hospital of Fudan University published the largest and longest-running clinical trial of gene therapy for hereditary hearing loss. The results, published in Nature, showed that a single injection of a viral vector carrying a functional copy of the OTOF gene restored measurable hearing in roughly 90% of 42 participants — some of whom could detect whispers — with benefits persisting for up to 2.5 years [1][2].

The findings mark a turning point for a field that has moved from animal models to human patients in under a decade. But the data also surface hard questions: about how long the effect lasts, who can access it, what it costs, and whether framing inherited deafness as a disease to be fixed is the right framework at all.

What the Trial Showed

The multicentre, single-arm trial enrolled 42 participants across eight hospitals in China, ranging in age from 0.8 to 32.3 years. All had autosomal recessive deafness 9 (DFNB9), caused by mutations in the OTOF gene, which encodes otoferlin — a protein essential for transmitting sound signals from hair cells in the inner ear to the auditory nerve. Without functional otoferlin, the ear's mechanical structures work normally but the electrical signal never reaches the brain [1][3].

Participants received an intracochlear infusion of AAV1-hOTOF (an adeno-associated virus serotype 1 carrying human otoferlin coding DNA) at one of three dose levels. Thirty-six received a unilateral injection; six were treated bilaterally [2].

The audiological improvements were substantial. Average click-evoked auditory brainstem response (ABR) thresholds — a measure of the softest sound the auditory system can detect — improved from 101 ± 1 dB at baseline to 48 ± 26 dB after treatment. Tone-burst ABR thresholds fell from 91 ± 4 dB to 57 ± 19 dB, and auditory steady-state response (ASSR) improved from 80 ± 14 dB to 64 ± 21 dB [1][3]. For context, normal hearing is defined as thresholds at or below 25 dB, while profound deafness begins above 90 dB.

Source: Nature (2026); NEJM (2024)

Data as of Apr 22, 2026CSV

Most participants began regaining hearing within weeks of treatment, with continued improvement over approximately six months and stability thereafter [2]. Younger children showed the greatest gains, while the three adult participants (including one aged 32.3 years) showed smaller but measurable recovery [4]. The six bilaterally treated participants achieved higher language and speech perception scores than those treated in one ear alone [2]. Approximately 10% of participants did not respond to treatment [4].

No serious treatment-related adverse events were reported. The most common side effect was a transient decrease in neutrophil count. No dose-limiting toxicities were observed [1][2].

The Competitive Landscape: Multiple Programs, Different Approaches

The Chinese trial is not the only effort. At least three separate gene therapy programs for OTOF-related deafness are now in clinical testing.

Source: Nature, NEJM, Nature Medicine

Data as of Apr 22, 2026CSV

Regeneron Pharmaceuticals is running the Phase I/II CHORD trial in the US and UK with DB-OTO, a therapy originally developed by Decibel Therapeutics, which Regeneron acquired in September 2023 [5]. In the CHORD trial, 11 of 12 children with profound OTOF-related deafness showed clinically meaningful hearing improvement, with three achieving normal hearing levels and nine reaching thresholds that would eliminate the need for cochlear implants. Six children could hear soft speech unaided, and three could detect whispers [6]. DB-OTO has received orphan drug designation, rare pediatric disease designation, fast track designation, and regenerative medicine advanced therapy (RMAT) designation from the FDA, as well as orphan drug designation from the European Medicines Agency [5][6]. Regeneron announced plans to file for FDA approval before the end of 2025 [5].

Eli Lilly, through its acquisition of Akouos for $487 million in October 2022, is developing AK-OTOF. Early data showed hearing restoration in an 11-year-old within 30 days, though the Phase I/II trial completion is not expected until October 2028 [6].

In China, the earlier trials conducted at Fudan University in Shanghai — first with six patients (published in The Lancet in January 2024) and then with five bilaterally treated children (published in Nature Medicine in June 2024) — laid the groundwork for the larger 42-patient multicentre study [7][8]. A separate 10-patient trial across five Chinese hospitals, funded in part by Otovia Therapeutics, showed an average improvement from 106 dB to 52 dB at six months, with one seven-year-old regaining near-full hearing within four months [9].

How Many Children Are Affected — and How Many Can Be Found

OTOF mutations account for an estimated 2–8% of all congenital genetic deafness, affecting roughly 200,000 individuals worldwide [10][3]. In the United States, the condition is estimated to affect 20–50 newborns annually [6].

The prevalence varies by population. In Saudi Arabia, two recurrent OTOF variants accounted for a third of genetically confirmed cases in one cohort, reflecting the higher rates of consanguinity in some communities [10]. In Spain, a specific OTOF mutation (p.Q829X) is unusually common among patients with prelingual sensorineural hearing loss [10].

Identifying these children early is a clinical challenge. Standard newborn hearing screening relies on otoacoustic emissions (OAEs) — sounds produced by the outer hair cells of a functioning cochlea. In OTOF-related deafness, OAEs are often initially present because the cochlea's mechanical function is intact; the deficit lies in the synaptic transmission. This means that OAE-based screening frequently misses OTOF-related hearing loss. Switching protocols to include ABR testing, which measures neural responses downstream of the synapse, would improve detection, but ABR is more time-consuming and expensive to administer at scale [10][11].

Even when hearing loss is detected, genetic diagnosis requires access to sequencing infrastructure. More than 219 pathogenic or likely pathogenic OTOF variants have been catalogued [10], and identifying the specific mutation is necessary to determine eligibility for gene therapy. In high-income countries with established genetic testing pipelines, this is feasible. In low- and middle-income countries — where OTOF mutations are prevalent, particularly in populations with high consanguinity rates — the infrastructure often does not exist [10][11].

The Cost Question

No trial sponsor has disclosed a projected price for OTOF gene therapy. But the economics of gene therapy more broadly provide a frame of reference. Recent single-dose gene therapies for other rare diseases have launched at prices ranging from $1.5 million to $3.5 million per patient.

By comparison, cochlear implantation — the current standard intervention for severe-to-profound hearing loss — costs $30,000 to $100,000 per ear in the United States, encompassing the device, surgery, hospitalization, and initial programming [12]. Lifetime costs, including device upgrades, battery replacements, programming sessions, and speech therapy, can significantly exceed the initial figure. A 2024 study in The Laryngoscope found that while medical costs were higher for cochlear implant recipients, the higher lifetime income earnings of implanted individuals offset the medical expense [12].

In low-income settings, the full treatment cost for cochlear implantation already exceeds what most families can afford without subsidized healthcare programs [12]. A gene therapy priced in the millions would be orders of magnitude less accessible in these same settings, despite the fact that consanguinity-driven OTOF mutations are most prevalent in regions of the Middle East, South Asia, and North Africa.

The counterargument from gene therapy proponents is that a single injection, if durable, could be more cost-effective over a lifetime than decades of cochlear implant maintenance and audiological support. Whether that argument holds depends entirely on how long the therapeutic effect persists — a question the current data cannot fully answer.

Durability and the Redosing Problem

The 2.5-year follow-up is the longest reported for any hearing gene therapy, but it remains short in the context of a treatment intended to last a lifetime [1]. AAV-mediated transgene expression has been shown to persist for years in some tissues, but durability varies significantly by cell type, organ, and vector serotype [13].

In the cochlea specifically, early animal studies showed that AAV-mediated expression was detectable at 2–24 weeks, though levels were relatively lower at 24 weeks compared to 2 weeks [13]. More recent longitudinal studies in mouse models over up to two years showed persistent expression in spiral ganglion neurons [13]. Whether this translates to decades of stable otoferlin production in human hair cells is unknown.

A separate concern is the immune response. AAV delivery to the cochlea can trigger infiltration of immune cells, with the magnitude depending on the specific AAV serotype and promoter used. Research published in 2025 found that CMV-driven vectors provoked stronger immune activation than CBA promoters, and AAV9 induced greater immunogenicity than AAV1 — the serotype used in the Chinese multicentre trial [14].

If the therapeutic effect fades, redosing presents a fundamental obstacle. Systemic AAV re-administration is generally considered infeasible because the initial dose generates neutralizing antibodies (NAbs) and T memory cells that attack the same or similar viral capsids on subsequent exposure, potentially destroying transgene expression entirely [13]. Whether local re-injection into the cochlea — a partially immune-privileged space — could circumvent this barrier is an open research question, but no redosing data from human participants has been reported.

Distinguishing genuine sustained improvement from other factors in pediatric patients is also methodologically difficult. Young children naturally develop auditory processing skills as their nervous systems mature, and some degree of measured improvement could reflect developmental trajectories rather than therapeutic effect. The trial investigators addressed this partly by including adult participants (who showed smaller but real gains) and by using objective electrophysiological measures like ABR alongside behavioral audiometry [1][4].

The Deaf Community's Objection — and Whether Anyone Is Listening

The development of gene therapies for inherited deafness has intensified a debate that has accompanied cochlear implants for decades. Members of the signing Deaf community, scholars in disability studies, and bioethicists have raised substantive objections to the framing of hereditary deafness as a pathology requiring medical correction.

Teresa Blankmeyer Burke, associate professor of philosophy at Gallaudet University — the world's only university designed for deaf and hard-of-hearing students — has articulated the strongest version of this argument. Burke contends that gene therapy for hereditary deafness "would result in smaller numbers of deaf children," reducing the critical mass of signing Deaf people needed for a flourishing linguistic and cultural community [15]. Unlike cochlear implants, which are reversible in the sense that a recipient can choose to stop using the device, gene therapy permanently alters genetic expression — a decision made for children "most likely without having had any input into the decision to change their genetic make-up" [15].

Burke challenges the unexamined assumption that "it is better to be a member of the dominant, mainstream Hearing cultural community than to be a member of the non-dominant Deaf cultural community" — a claim she describes as "frequently stated but rarely argued for" [15].

A 2025 commentary in The Lancet asked directly: "Gene therapy: who should decide the Deaf community's future?" [16]. The piece noted that throughout Deaf history, many individuals have faced rejection of their Deaf identity and have been forbidden to use sign language. Previous hearing technologies, including cochlear implants and hearing aids, have been viewed by some community members as "agents of suppression of their Deaf identity" [17].

Critics of gene therapy from within the Deaf community point out that the therapy currently addresses only 2–8% of genetic deafness subtypes, limiting its population-level impact. The concern is less about the absolute numbers than about the normative message: that deafness is a deficiency to be eliminated rather than a form of human variation [17].

Researchers involved in the trials have generally responded that gene therapy does not constitute "a call to eliminate signed language communities" and that characterizing research this way is a "hyperbolic category mistake" [15]. But published trial protocols, consent documents, and ethics board deliberations have not, to date, shown evidence of systematic engagement with Deaf community scholars or organizations during trial design. The 2025 Lancet commentary was published after the trials were already underway [16].

Research Output and Scientific Momentum

The scientific interest in gene therapy for deafness has surged. According to OpenAlex data, publications on the topic more than doubled between 2019 (1,190 papers) and 2024 (2,481 papers). The 2026 total so far — 486 papers as of April — suggests continued activity, though the year-over-year comparison is incomplete [18].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Conflicts of Interest and Funding

The multicentre Chinese trial was funded by Chinese research programs, and the 10-patient trial at five Chinese hospitals was funded in part by Otovia Therapeutics, which developed the gene therapy and employs many of the researchers involved [9]. This is a common arrangement in gene therapy trials, where the companies developing the vectors often fund the academic investigators testing them. Regeneron, as a publicly traded pharmaceutical company, has disclosed its financial relationships with CHORD trial investigators through standard clinical trial transparency mechanisms [5][6].

Whether lead investigators hold equity stakes in the companies whose products they are testing is a question that varies by trial and jurisdiction. US-based trials are subject to FDA conflict-of-interest disclosure rules. Chinese clinical trial regulations have been tightening in recent years but historically have had less stringent public disclosure requirements for investigator financial ties.

The Regulatory Road Ahead

Regeneron's DB-OTO is the furthest along the regulatory path in the West, with an FDA submission planned by end of 2025 and multiple expedited designations already in hand [5][6]. If approved, it would become the first gene therapy for any form of hearing loss. The European Medicines Agency has granted orphan drug designation, but a specific approval timeline for the EU has not been disclosed [5].

In China, the regulatory environment is distinct. The National Medical Products Administration (NMPA) has shown willingness to move quickly on gene therapies, and the Chinese trials have generated the largest datasets. Whether the AAV1-hOTOF therapy tested in the multicentre trial will pursue NMPA approval — and under what commercial arrangement — remains unclear.

Eli Lilly's AK-OTOF program is earlier-stage, with Phase I/II completion projected for October 2028, placing it years behind Regeneron and the Chinese programs [6].

Key data gaps remain for all programs. No trial has yet reported results from a randomized controlled study — all published data come from single-arm trials without placebo or active comparator groups. Regulators may require or accept single-arm data given the severity of the condition and the lack of alternative treatments for OTOF-specific deafness, but the absence of controlled data makes it harder to quantify the treatment effect precisely.

What Happens If It Stops Working

The question that no trial has yet answered is what happens at year 5, or year 10, or year 20. If AAV transgene expression diminishes — as it can in other tissues — patients who received the therapy as infants would face hearing loss as children or teenagers, at an age when they may have built their lives around spoken language rather than sign.

No patients in the published cohorts have required retreatment or shown measurable regression on audiological measures at the 2.5-year mark [1]. But 2.5 years is a fraction of the timespan over which durability matters. The immune barriers to redosing mean that if the therapy fails, the same vector likely cannot be administered again [13]. Alternative rescue strategies — including different AAV serotypes, non-viral delivery methods, or cochlear implantation as a backup — have not been prospectively studied in post-gene-therapy patients.

For now, the data support cautious optimism: a single injection can restore meaningful hearing in most patients with OTOF-related deafness, with the effect persisting over the medium term. Whether that medium-term result extends to a lifetime of stable hearing — and whether the therapy can be made accessible to the populations that need it most — will determine whether this becomes a standard treatment or remains a proof of concept available to a few.